Smith & Nephew, J&J Orthopaedics Merger Collapses Over Leadership Dispute
A proposed $34 billion transatlantic merger between UK-listed Smith & Nephew and Johnson & Johnson's orthopaedics unit failed in mid-October 2026 due to disagreement over who would lead the combined company.
Original PrimaryBrief article graphic. Not a photograph of the event.
THE PRIMARY BRIEF
01 · The primary finding
A proposed $34 billion transatlantic merger between UK-listed Smith & Nephew and Johnson & Johnson's orthopaedics unit collapsed in mid-October 2026 due to an intractable dispute over who would lead the combined entity.
02 · The primary evidence
Johnson & Johnson insisted its DePuy Synthes worldwide president, Namal Nawana, become CEO, while Smith & Nephew's chair, Rupert Soames, made keeping its current CEO, Deepak Nath, a "red line" in negotiations.
03 · Why it matters
The failure of this major medical technology deal forces both companies to pursue alternative strategies, with J&J now leaning towards spinning off its orthopaedics unit and Smith & Nephew facing continued investor pressure and underperforming shares.
26 cited sources · 24 independent publishers
UK-listed Smith & Nephew and Johnson & Johnson's orthopaedics unit, DePuy Synthes, ended their proposed $34 billion transatlantic merger in mid-October 2026 due to an unresolved dispute over who would lead the combined company. This collapse leaves both medical technology companies to pursue separate strategies, impacting their market positions and future growth in the competitive orthopaedics sector.